AgeX Therapeutics

Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics

Retrieved on: 
Tuesday, March 26, 2024
AgeX Therapeutics, CUSIP, IND, Gibson Dunn, Therapy, Interim, ADC, FDA, LNP, DSM-IV codes, Food, Pharmaceutical industry

The combined company will operate under the name Serina Therapeutics and will trade on the NYSE American market under the ticker symbol “SER” effective with the open of business on Wednesday, March 27, 2024.

Key Points: 
  • The combined company will operate under the name Serina Therapeutics and will trade on the NYSE American market under the ticker symbol “SER” effective with the open of business on Wednesday, March 27, 2024.
  • The new CUSIP number for the combined company following the merger is 81751A108.
  • Serina Board Chair J. Milton Harris, Ph.D., stated, “This merger is the culmination of years of work on the part of the Serina team and enables us to move our lead polyoxazoline-drug conjugate into clinical trials.
  • Bradley Arant Boult Cummings LLP provided legal counsel to Serina.

AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results

Retrieved on: 
Friday, March 22, 2024
Research, Separation, Biotechnology, Regeneration, AgeX Therapeutics, Finance, Exchange, Accounting standard, Insurance, Bank statement, ASC, Therapy, Patent, Private law, Consultant, Ageing

ALAMEDA, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for fourth quarter and the full year ended December 31, 2023 and recent highlights.

Key Points: 
  • ALAMEDA, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for fourth quarter and the full year ended December 31, 2023 and recent highlights.
  • The Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of AgeX common stock on February 1, 2024.
  • As of December 31, 2023, AgeX owed Juvenescence Limited $4.5 million in principal and origination fees on account of loans extended to AgeX.
  • Operating expenses for the full year 2023 were $10.1 million as compared with $7.0 million in the same period of 2022.

AGEX THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AgeX Therapeutics, Inc. - AGE

Retrieved on: 
Tuesday, February 27, 2024
Class Action Lawsuit, Professional Services, Legal, KSF, AgeX Therapeutics, Sale, Therapy

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

Key Points: 
  • Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of AgeX Therapeutics, Inc. (NYSE: AGE) with Serina Therapeutics, Inc. pursuant to which AgeX shareholders are expected to own approximately 25% of the newly combined company.
  • KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

AgeX Therapeutics Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 14, 2023
Research, Other Health, Pharmaceutical, Consumer Electronics, Consumer, Technology, Science, Biotechnology, Stem Cells, Seniors, Health, Diabetes, Other Science, Sale, Classification, NYSE, AgeX Therapeutics, Therapy, Preferred stock, Regeneration, Bank statement, Security agreement, Agreement, ASC, Accounting standard, Exchange, GAAP, Private law, Finance, Ageing, Security, Plan, Sino-Japanese Journalist Exchange Agreement, Pharmaceutical industry, Security (finance)

AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter and nine months ended September 30, 2023.

Key Points: 
  • AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter and nine months ended September 30, 2023.
  • On October 31, 2023, AgeX made a final draw of loan funds available under a line of credit from Juvenescence Limited.
  • Cash, cash equivalents, and restricted cash totaled $0.4 million as of September 30, 2023.
  • These factors raise substantial doubt regarding the ability of AgeX to continue as a going concern.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RPT, NXGN, AGE, SMMF

Retrieved on: 
Sunday, October 29, 2023
Sale, AgeX Therapeutics, NYSE, Kimco Realty, RPT, Fraud, Advertising, Thoma Bravo, NextGen Healthcare, Nextgen, RPT Realty, Therapy, Security (finance)

If you are a RPT shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a RPT shareholder, click here to learn more about your rights and options .
  • If you are a NextGen shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – AGE, AVTA, SPLK, CNSL

Retrieved on: 
Friday, October 27, 2023
Cisco, Sale, AGE, NYSE, Empire, AgeX Therapeutics, CNSL, Monteverde, Searchlight Capital, Acquisition, AVTA, Therapy, Security (finance)

Under the terms of the agreement, AGE shareholders are expected to own approximately 25% of the combined company.

Key Points: 
  • Under the terms of the agreement, AGE shareholders are expected to own approximately 25% of the combined company.
  • It is free and there is no cost or obligation to you.
  • Under the terms of the agreement, AVTA shareholders are expected to receive $26.00 in cash per share they own.
  • Under the terms of the agreement, CNSL shareholders are expected to receive $4.70 in cash per share they own.

ALERT: The M&A Class Action Firm Continues Investigating the Merger – AGE, NEWR, SPLK, AVTA

Retrieved on: 
Wednesday, October 18, 2023
Cisco, Sale, AGE, NYSE, Empire, AgeX Therapeutics, Monteverde, Francisco Partners, Acquisition, AVTA, Therapy, New Relic, Security (finance)

Under the terms of the agreement, AGE shareholders are expected to own approximately 25% of the combined company.

Key Points: 
  • Under the terms of the agreement, AGE shareholders are expected to own approximately 25% of the combined company.
  • It is free and there is no cost or obligation to you.
  • Under the terms of the agreement, SPLK shareholders are expected to receive $157.00 in cash per share they own.
  • Under the terms of the agreement, AVTA shareholders are expected to receive $26.00 in cash per share they own.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RPT, HT, ABCM, AGE

Retrieved on: 
Sunday, October 8, 2023
Abcam, Danaher Corporation, NYSE, Kimco Realty, Fraud, AgeX Therapeutics, Advertising, Therapy, RPT, Sale, KSL Capital Partners, RPT Realty, Security (finance), Hersha Hospitality Trust

If you are a RPT shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a RPT shareholder, click here to learn more about your rights and options .
  • Hersha Hospitality Trust (NYSE: HT)’s sale to affiliates of KSL Capital Partners, LLC for $10.00 per share.
  • If you are a Hersha shareholder, click here to learn more about your rights and options .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NXGN, AVTA, AGE, THRN

Retrieved on: 
Thursday, September 28, 2023
NextGen Healthcare, AgeX Therapeutics, Nextgen, Sale, Advertising, Thoma Bravo, Fraud, Therapy, NYSE, Security (finance)

If you are a NextGen shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a NextGen shareholder, click here to learn more about your rights and options .
  • If you are an Avantax shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

ALERT: The M&A Class Action Firm Continues Investigating the Merger – CATC, AGE, NEWR, ESTE

Retrieved on: 
Thursday, September 28, 2023
Permian, New Relic, AGE, Empire, Sale, Francisco Partners, Monteverde, Dakota Territory Resource Corp, AgeX Therapeutics, Therapy, NYSE, CATC, Security (finance)

Under the terms of the agreement, CATC shareholders will receive 4.956 shares of Eastern per share they own.

Key Points: 
  • Under the terms of the agreement, CATC shareholders will receive 4.956 shares of Eastern per share they own.
  • AgeX Therapeutics, Inc. (NYSE: AGE ), relating to its proposed merger with Serina Therapeutics, Inc.
  • Earthstone Energy, Inc. (NYSE: ESTE ), relating to its proposed merger with Permian Resources Corp.
  • Under the terms of the agreement, ESTE shareholders will receive 1.446 shares of Permian per share they own.